FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2093557029> ?p ?o ?g. }

• W2093557029 endingPage "226" @default.
• W2093557029 startingPage "219" @default.
• W2093557029 abstract "Pancreatic ductal adenocarcinoma is frequently associated with aberrant activation of the Ras/Raf/MAPK pathway and cyclooxygenase-2 (COX-2) overexpression. This study evaluated the potential for combining the multikinase inhibitor sorafenib and the specific COX-2 inhibitor celecoxib as therapy in pancreatic ductal adenocarcinoma cells.BxPC-3, MIAPaCa-2, PANC-1 and AsPC-1 pancreatic adenocarcinoma cells were exposed to sorafenib and celecoxib combined treatment in vitro. Cell viability and various growth promoting and survival signaling pathways were monitored by MTT, flow cytometry and Western blotting.Combined treatment with sorafenib and celecoxib synergistically inhibited pancreatic adenocarcinoma cell proliferation. This regimen produced combination index (CI) values between 0.67 and 0.92 for the various cell lines, indicating significant synergistic interactions between sorafenib and celecoxib, which also markedly inhibited the migratory capacity. The growth inhibition was associated with an accumulation of cells in the G(0)/G(1) phase of the cell cycle and induction of apoptosis. These changes were accompanied by a significant reduction of p21(WAF1/Cip1) levels, where celecoxib sensitized the cells to sorafenib-mediated p21(WAF1/Cip1) suppression.These results suggest that combined treatment with sorafenib and celecoxib synergistically induce growth inhibition and apoptosis in pancreatic adenocarcinoma cells through a process involving p21(WAF1/Cip1) suppression." @default.
• W2093557029 created "2016-06-24" @default.
• W2093557029 creator A5016158638 @default.
• W2093557029 creator A5023845153 @default.
• W2093557029 creator A5049416351 @default.
• W2093557029 creator A5054165373 @default.
• W2093557029 creator A5072275700 @default.
• W2093557029 date "2012-05-01" @default.
• W2093557029 modified "2023-09-25" @default.
• W2093557029 title "Celecoxib synergizes human pancreatic ductal adenocarcinoma cells to sorafenib-induced growth inhibition" @default.
• W2093557029 cites W1931508686 @default.
• W2093557029 cites W1972305847 @default.
• W2093557029 cites W1992360356 @default.
• W2093557029 cites W1998151620 @default.
• W2093557029 cites W2009495905 @default.
• W2093557029 cites W2026707626 @default.
• W2093557029 cites W2053290453 @default.
• W2093557029 cites W2060979922 @default.
• W2093557029 cites W2064446750 @default.
• W2093557029 cites W2074840148 @default.
• W2093557029 cites W2081149508 @default.
• W2093557029 cites W2085250471 @default.
• W2093557029 cites W2087408588 @default.
• W2093557029 cites W2105372476 @default.
• W2093557029 cites W2106787323 @default.
• W2093557029 cites W2116177733 @default.
• W2093557029 cites W2116394959 @default.
• W2093557029 cites W2140765540 @default.
• W2093557029 cites W2141528632 @default.
• W2093557029 cites W2145704036 @default.
• W2093557029 cites W2147344769 @default.
• W2093557029 cites W2149026055 @default.
• W2093557029 cites W2150489636 @default.
• W2093557029 cites W2151214205 @default.
• W2093557029 cites W2158134441 @default.
• W2093557029 cites W2164034599 @default.
• W2093557029 cites W2168227773 @default.
• W2093557029 cites W2185138096 @default.
• W2093557029 cites W2332325099 @default.
• W2093557029 cites W4244578979 @default.
• W2093557029 doi "https://doi.org/10.1016/j.pan.2012.04.005" @default.
• W2093557029 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22687377" @default.
• W2093557029 hasPublicationYear "2012" @default.
• W2093557029 type Work @default.
• W2093557029 sameAs 2093557029 @default.
• W2093557029 citedByCount "10" @default.
• W2093557029 countsByYear W20935570292013 @default.
• W2093557029 countsByYear W20935570292014 @default.
• W2093557029 countsByYear W20935570292015 @default.
• W2093557029 countsByYear W20935570292016 @default.
• W2093557029 countsByYear W20935570292018 @default.
• W2093557029 countsByYear W20935570292019 @default.
• W2093557029 crossrefType "journal-article" @default.
• W2093557029 hasAuthorship W2093557029A5016158638 @default.
• W2093557029 hasAuthorship W2093557029A5023845153 @default.
• W2093557029 hasAuthorship W2093557029A5049416351 @default.
• W2093557029 hasAuthorship W2093557029A5054165373 @default.
• W2093557029 hasAuthorship W2093557029A5072275700 @default.
• W2093557029 hasConcept C121608353 @default.
• W2093557029 hasConcept C126322002 @default.
• W2093557029 hasConcept C181199279 @default.
• W2093557029 hasConcept C190283241 @default.
• W2093557029 hasConcept C2776467144 @default.
• W2093557029 hasConcept C2777031258 @default.
• W2093557029 hasConcept C2778019345 @default.
• W2093557029 hasConcept C2778695046 @default.
• W2093557029 hasConcept C2779689624 @default.
• W2093557029 hasConcept C2781182431 @default.
• W2093557029 hasConcept C29537977 @default.
• W2093557029 hasConcept C502942594 @default.
• W2093557029 hasConcept C55493867 @default.
• W2093557029 hasConcept C62112901 @default.
• W2093557029 hasConcept C71924100 @default.
• W2093557029 hasConcept C86803240 @default.
• W2093557029 hasConcept C98274493 @default.
• W2093557029 hasConceptScore W2093557029C121608353 @default.
• W2093557029 hasConceptScore W2093557029C126322002 @default.
• W2093557029 hasConceptScore W2093557029C181199279 @default.
• W2093557029 hasConceptScore W2093557029C190283241 @default.
• W2093557029 hasConceptScore W2093557029C2776467144 @default.
• W2093557029 hasConceptScore W2093557029C2777031258 @default.
• W2093557029 hasConceptScore W2093557029C2778019345 @default.
• W2093557029 hasConceptScore W2093557029C2778695046 @default.
• W2093557029 hasConceptScore W2093557029C2779689624 @default.
• W2093557029 hasConceptScore W2093557029C2781182431 @default.
• W2093557029 hasConceptScore W2093557029C29537977 @default.
• W2093557029 hasConceptScore W2093557029C502942594 @default.
• W2093557029 hasConceptScore W2093557029C55493867 @default.
• W2093557029 hasConceptScore W2093557029C62112901 @default.
• W2093557029 hasConceptScore W2093557029C71924100 @default.
• W2093557029 hasConceptScore W2093557029C86803240 @default.
• W2093557029 hasConceptScore W2093557029C98274493 @default.
• W2093557029 hasIssue "3" @default.
• W2093557029 hasLocation W20935570291 @default.
• W2093557029 hasLocation W20935570292 @default.
• W2093557029 hasOpenAccess W2093557029 @default.
• W2093557029 hasPrimaryLocation W20935570291 @default.
• W2093557029 hasRelatedWork W2349027124 @default.

• next